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Definition
Two types of tumour lysis syndrome (TLS) ;
1. Laboratory TLS:
 25% increase in potassium,phosphate and uric acid,or 
decline in calcium from baseline .
 Occur within 4 days of initiating chemotherapy.
 Patients on standard of care. 
 Minimum of two out of four criteria.
Hande and Garrow 1993
2. Clinical tumour lysis syndrome
Laboratory TLS plus renal failure, cardiac
arrhythmias or sudden death .
 A new definition has been suggested by Cairo
and Bishop to include values above upper
limit of normal.
 Study used Hande and Garrow definition.
Cairo and Bishop 2004
PREDICTORS OF TLS
• Tumor factors
• Treatment factors
• Patient factors
– Postgrad Med J.1981;57:727-729
STUDIES ON TLS
Incidence References
Hyperuricemia 14%-70%. Haas1999
emedicine.com2003
Azotemia 3- 7.5% Carl et al, Arch Inter 
Med.1974;133:349-359
Hyperkalemia,
Hyperphosphatemia
and hypocalcaemia
11-38% Cohen et al Am J
Med1980;68:486-91
METHODOLOGY
Serum potassium,phosphate, uric acid and calcium
were were determined on day 1 and then 24 hourly for
4 days.
Tests were repeated on the 7th day in those
developing TLS to check resolution.
If no resolution,tests were repeated on the 15th day.
METHODOLOGY CTD
Inclusion Criteria
•Patients aged 13 years and above
•Tissue diagnosis of cancer.
•Patients receiving the first course of chemotherapy.
Exclusion Criteria
•Patients on treatment for gout.
•Post-renal transplant patients.
•Unwillingness to come back to the Hospital for four
consecutive days.
•Dehydrated patients .
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RESULTS
TUMOUR
Number STAGE
Non-Hodgkin’s 
lymphoma
8
7
3
IV
III
II
Hodgkin’s
lymphoma
2
4
IV
III
Chronic lymphocytic
Leukemia
8 IV
Breast cancer 18
17
9
1
IV
III
II
I
Others 13 IV
No staging 
(AML,ALL,MM)
21 -------
Total 111 --------
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TLS IN HAEMATOLOGICAL AND NON-HAEMATOLOGICAL 
TUMOURS 
.
HAEMATOLOGICAL NON 
HAEMATOLOGICAL
TOTAL P VALUE
POSITIVE 40 (75.47%) 2 (3.45%) 42 <0.001
NEGATIVE 13 (24.53%) 56 (96.55%) 69
TOTAL 53 (100%) 58 (100) 111
DISCUSSION
Incidence of TLS found in this study was 37.8%.
About 720    patients receive chemotherapy annually.
This means that about 273 patients are at risk of TLS per year.
Case fatality rate of 4.76% may translate to 13 deaths per year. 
Preventable and treatable condition
DISCUSSION CTD
•Association between  potassium and phosphate 
quite remarkable. Need for further study 
•The absence of hyperuricemia is unusual
•Use of allopurinol prophylaxis in all the patients 
at risk
• Could the results have been different without 
allopurinol prophylaxis? 
 Moderate hyperphosphatemia was insufficient 
to cause hypocalcemia 
CONCLUSIONS:
Tumour lysis syndrome is common at KNH (38.7%).
It mainly occurs in haematological malignancies.
Most cases of tumour lysis syndrome occur on the
first day of chemotherapy.
Hyperkalemia and hyperphosphatemia are the main
manifestations of TLS at KNH.
RECOMMENDATIONS:
1) All patients with haematological malignancies
receiving chemotherapy should have their electrolytes
monitored for at least two days after initiation of
therapy.
2) Patients who cannot afford to pay for uric acid,
calcium, phosphate and potassium can be monitored for
hyperkalemia alone.
3) Allopurinol prophylaxis should be continued.
4) Continous retrospective analysis of TLS data.
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